Extended dicer substrate agents and methods for the specific inhibition of gene expression
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
1. An isolated double stranded nucleic acid comprising:
a first oligonucleotide strand having a 5′ terminus and a 3′ terminus and a second oligonucleotide strand having a 5′ terminus and a 3′ terminus, wherein each said 5′ terminus comprises a 5′ terminal nucleotide and each said 3′ terminus comprises a 3′ terminal nucleotide; and
an extended loop at the 3′ terminus of said first strand or the 5′ terminus of said second strand;
wherein said first strand is 35-60 nucleotide residues in length;
wherein said second strand is 19-39 nucleotide residues in length;
wherein from 1-30 consecutive nucleotides, including the 5′ terminal nucleotide, of said first strand are unpaired with the 3′ terminus of said second strand, thereby forming a 1-30 nucleotide single stranded 5′ overhang on said first strand;
wherein said first strand is annealed to said second strand to form a duplex region of 18-30 base pairs; and
wherein said second strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of said second strand length to reduce target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
2. The isolated double stranded nucleic acid of claim 1 , wherein at least one nucleotide of said first strand between and including said first strand positions 24 to the 3′ terminal nucleotide residue of said first strand is a deoxyribonucleotide that base pairs with said second strand.
3. The isolated double stranded nucleic acid of claim 1 , wherein at least 10 consecutive nucleotides and at most 15 consecutive nucleotides, including the 5′ terminal nucleotide of said first strand are unpaired with the 3′ terminus of said second strand, thereby forming a 10-15 nucleotide single stranded 5′ overhang.
4. The isolated double stranded nucleic acid of claim 1 , wherein at least one nucleotide of said second strand between and including second strand nucleotides corresponding to and thus base paired with first strand positions 24 to the 3′ terminal nucleotide residue of said first strand is a ribonucleotide.
5. The isolated double stranded nucleic acid of claim 1 , wherein said duplex between said first and second strands comprises a fully duplexed region having no unpaired bases.
6. The isolated double stranded nucleic acid of claim 1 , wherein said duplex between said first and second strands comprises an unpaired base pair selected from the group consisting of: 1 unpaired base pair; 2 unpaired base pairs, 3 unpaired base pairs, 4 unpaired base pairs, and 5 unpaired base pairs.
7. The isolated double stranded nucleic acid of claim 6 , wherein said unpaired base pairs are consecutive or non-consecutive.
8. The isolated double stranded nucleic acid of claim 1 , wherein said first strand is up to 60 nucleotides in length, and the nucleotides of said first strand 3′ to position 23 of said first strand comprises deoxyribonucleotides selected from the group consisting of: two, three, four, five, and six nucleotide residues of positions 24 to the 3′ terminal nucleotide residue of said first strand are deoxyribonucleotides.
9. The isolated double stranded nucleic acid of claim 8 , wherein said deoxyribonucleotides are consecutive deoxyribonucleotides.
10. The isolated double stranded nucleic acid of claim 1 , wherein two or more consecutive nucleotide residues of positions 24 to 30 of said first strand are deoxyribonucleotides that base pair with nucleotides of said second strand.
11. The isolated double stranded nucleic acid of claim 10 , wherein said first strand is up to 60 nucleotides in length and comprises a pair of deoxyribonucleotides selected from the group consisting of: positions 24 and 25, positions 25 and 26, positions 26 and 27, positions 27 and 28, positions 28 and 29, and positions 29 and 30, wherein said first pair of deoxyribonucleotides is base paired with a corresponding pair of nucleotides of said second strand.
12. The isolated double stranded nucleic acid of claim 1 , wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 28 of said first strand comprise at least 8 ribonucleotides.
13. The isolated double stranded nucleic acid of claim 1 , wherein said first strand 5′ overhang is selected from the group consisting of: 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30 nucleotides in length.
14. The isolated double stranded nucleic acid of claim 1 , wherein said first strand 5′ overhang comprises a ribonucleotide or deoxyribonucleotide.
15. The isolated double stranded nucleic acid of claim 14 , wherein all nucleotides of said first strand 5′ overhang are deoxyribonucleotides.
16. The isolated double stranded nucleic acid of claim 13 , wherein said nucleotides of said first strand 5′ overhang comprise a phosphate backbone modification.
17. The isolated double stranded nucleic acid of claim 16 , wherein said phosphate backbone modification is selected from the group consisting of a phosphonate, a phosphorothioate, a phosphotriester, a methylphosphonate, a locked nucleic acid, a morpholino and a bicyclic furanose analog.
18. The isolated double stranded nucleic acid of claim 17 , wherein the 5′ terminal nucleotide of said first strand is a ribonucleotide.
19. The isolated double stranded nucleic acid of claim 1 , wherein said nucleotides of said first strand 5′ overhang comprise a modified nucleotide.
20. The isolated double stranded nucleic acid of claim 19 , wherein said modified nucleotide residue is selected from the group consisting of 2′-O-methyl, 2′-methoxyethoxy, 2′-fluoro, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)2-O-2′-bridge, 2′-LNA, 2′-amino and 2′-O—(N-methylcarbamate).
21. The isolated double stranded nucleic acid of claim 20 , wherein said modified nucleotide of said first strand 5′ overhang is a 2′-O-methyl ribonucleotide.
22. The isolated double stranded nucleic acid of claim 1 , wherein a nucleotide of said second or first oligonucleotide strand is substituted with a modified nucleotide that directs the orientation of Dicer cleavage.
23. The isolated double stranded nucleic acid of claim 1 , wherein the first strand has a nucleotide sequence that is at least 80%, 90%, 95% or 100% complementary to the second strand nucleotide sequence.
24. The isolated double stranded nucleic acid of claim 1 , wherein said target RNA is KRAS.
25. A pharmaceutical composition for reducing expression of a target gene in a cell of a subject comprising an isolated double stranded nucleic acid as claimed in claim 1 in an amount effective to reduce expression of a target gene in a cell in comparison to a reference dsRNA and a pharmaceutically acceptable carrier.
26. A method of synthesizing a double stranded nucleic acid as claimed in claim 19 , comprising chemically or enzymatically synthesizing said double stranded nucleic acid.
27. The isolated double stranded nucleic acid of claim 1 , wherein said second strand is 26-36 nucleotide residues in length.
28. The isolated double stranded nucleic acid of claim 1 , wherein the second strand starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of said first strand to form a duplex.
29. The isolated double stranded nucleic acid of claim 1 , wherein the double-stranded nucleic acid is conjugated to a non-nucleic acid moiety.
30. The isolated double stranded nucleic acid of claim of claim 29 , wherein the non-nucleic acid moiety is a peptide or an organic compound.
31. The isolated double stranded nucleic acid of claim 1 , wherein the extended loop is a tetraloop.
32. The isolated double stranded nucleic acid of claim 31 , wherein the extended loop links the first and second strand.